RonanRx launches vertically integrated pharma platform for personalized GLP‑1 and peptide therapies

Lloyd, one of the co‑founders of RonanRx, announced the launch of a vertically integrated pharmaceutical venture that combines drug manufacturing, telehealth, electronic health records and delivery under a single software‑driven platform. Drawing on his experience running a large‑scale mask production facility during the COVID‑19 pandemic—where machine‑learning and computer‑vision tools were used to optimize a plant capable of producing a million masks per day—Lloyd applied a similar digital approach to pharmaceutical manufacturing. The new company will begin by producing GLP‑1 agonists and other peptide therapies, offering customized compounding that aligns dosage with individual patient responses, while maintaining a continuous feedback loop between patients, physicians and the manufacturing process.

RonanRx’s model aims to streamline the fragmented pharmaceutical supply chain by owning the entire stack from molecule synthesis to prescription, dispensing and home delivery, thereby reducing costs for consumers by three to ten times compared with traditional channels. The firm collects medical records, medication histories, laboratory results and wearable data to inform real‑time adjustments to therapy, positioning itself as a “software‑first” pharmacy that can rapidly adapt to patient‑specific needs. The company seeks input from professionals with experience in pharmacy operations, regulated software, clinical infrastructure or electronic health‑record systems to validate its assumptions and refine its integrated approach.